Goldman Sachs' recent list of eight "disruptive technologies" included
new therapies to fight cancer, drugs that promise to upend the pharma
industry in the next few decades. Most promising is immunotheraphy, an
approach being researched and advanced by Bristol-Myers (NYSE:BMY), Merck (NYSE:MRK), and Roche (Nasdaq:RHHBY),
among others. While these drugs aren't cancer cures, they appear to be
on pace to deliver significant improvements in the length of time cancer
patients can expect to live, with a relatively tolerable side-effects.
Read the full article here:
http://www.investopedia.com/articles/investing/082013/will-immunotherapy-disrupt-oncology-market.asp
No comments:
Post a Comment